What are your top takeaways from AAD 2026?

1. Cutaneous lupus erythematosus - the pipeline is very exciting and many mentions of the FDA breakthrough status of litifilimab. Also, talks on potentially using anifrolumab sooner in the treatment ladder to prevent scarring, which is approved for SLE and currently in trials for CLE. The clinical tri...

• Roy Geronemus lectured on increasing the frequency of treating babies with port wine stains daily x 5 days — since their hemoglobin at that age doesn’t get purpura. And then typically it’s just the eyebrow that is left.
• David Ozog discussed using botulinum toxin A injections in 3 circumstances. 1. F...

AI is here to stay. We as dermatologists need to understand its pros and cons and how to positively integrate it into our practices.